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Abstract Inorganic arsenic (iAs) poses a major threat to
worldwide human health, and yet the molecular mecha-
nisms underlying the toxic effects associated with iAs ex-
posure are not well understood. There is increasing exper-
imental evidence indicating that epigenetic modifications
may play a major role in the development of diseases
associated with exposure to environmental toxicants. Re-
search in the field has firmly established that iAs exposure
is associated with epigenetic alterations including changes
in DNA methylation, miRNA abundance, and post-
translational histone modifications. Here, we summarize
recent studies that have expanded the current knowledge
of these relationships. These studies have pinpointed spe-
cific regions of the genome and genes that are targets of
arsenical-induced epigenetic changes, including those as-
sociated with in utero iAs exposure. The recent literature
indicates that iAs biotransformation likely plays an impor-
tant role in the relationship between iAs exposure and the
epigenome, in addition to the sex and genetic background
of individuals. The research also shows that relatively low
to moderate exposure to iAs is associated with epigenetic
effects. However, while it is well established that arsenicals
can alter components of the epigenome, in many cases, the
biological significance of these alterations remains un-
known. The manner by which these and future studies
may help inform the role of epigenetic modifications in
the development of iAs-associated disease is evaluated
and the need for functional validation emphasized.
Keywords Arsenic . DNAmethylation . Histone
post-translational modifications .MicroRNAs . Epigenetic
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Introduction
Exposure to arsenic is a major global threat to human health.
Themost common route of exposure worldwide is through the
consumption of drinking water contaminated with naturally-
occurring, geologic sources of inorganic arsenic (iAs) [1].
Although the World Health Organization (WHO) has recom-
mended that levels of iAs in drinking water should not exceed
10 ppb, it is estimated that over 100 million people worldwide
are exposed to iAs levels in drinking water that are considered
detrimental to human health [2, 3]. Numerous chronic condi-
tions, such as cardiovascular and peripheral vascular disease,
diabetes mellitus, neurological effects, and cancers of the skin,
lung, liver, urinary bladder and prostate, may develop after
long-term iAs exposure [4]. Much remains to be learned about
the factors that influence susceptibility of chronically-exposed
individuals to these varied adverse health effects, but they
likely include individual genetic background, nutritional sta-
tus, toxicant co-exposure, the dose and duration of iAs expo-
sure, and capacity of individuals to biotransform iAs to reac-
tive metabolites [5, 6].
The molecular mechanisms underlying the diverse health
effects associated with iAs exposure are not well understood
and are likely complex. Numerous toxic effects have been
attributed to exposure to iAs and its reactive metabolites. For
instance, the generation of reactive oxygen species (ROS) is
believed to play a major role in mediating the toxic effects of
various arsenicals by causing biomolecular damage and the
activation of cellular signaling pathways that promote disease
development [7]. However, as no single mechanism has been
identified to date as a key event in the development of any
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iAs-associated disease, it is plausible that several mechanisms
are involved, possibly acting sequentially, simultaneously,
and/or synergistically.
In recent years, there has been increased recognition of the
importance of the epigenome in maintaining cellular homeo-
stasis, and therefore it has been hypothesized that
environmentally-induced epigenetic perturbations may play
an important role in disease development. Detailed descrip-
tions of the various components of the epigenome are outside
the scope and purpose of this work but are the subjects of
reviews elsewhere [8, 9]. Briefly, the epigenome refers to
potentially heritable biological information contained outside
the DNA sequence that functions as regulators of gene func-
tion [8–10]. The most extensively-studied components of the
epigenome include DNA methylation and covalent histone
post-translational modifications (PTMs), which regulate gene
expression at the transcriptional level. In recent years,
microRNAs (miRNAs) have been increasingly recognized
as another component of the epigenome. As they regulate
mRNA levels primarily at the post-transcriptional level and
as they act “above the genome” to control gene expression,
they are included in this review. Through their roles in regu-
lating gene expression, each of these components therefore
plays a critical role in maintaining cellular homeostasis by
interacting in coordinated responses to regulate organismal
development, maintain genetic stability, and mediate re-
sponses to environmental stressors [11–13].
The recognition that epigenetic changes may mediate the
toxic effects of iAs stems in part from the observation that it is
a potent carcinogen but not a point mutagen. The long-term
health consequences of prenatal iAs exposure also support
that iAs may exert adverse effects via epigenetic mechanisms.
In both humans and animal models, exposure to iAs in utero is
associated with increased risk for chronic disease develop-
ment later in life [14–16]. In animal models, experimental
evidence suggested this altered disease susceptibility was not
associated with changes in DNA sequence, but instead, per-
sistent changes in the expression and epigenetic landscape of
critical genes, including those implicated in chronic disease
development [17, 18]. Observations such as these are in line
with the hypothesis that environmental influences in utero
play a major role in the fetal origins of adult disease by
causing permanent changes, or “reprogramming,” of the epi-
genome in the fetal environment that persist throughout life
[13, 19]. These epigenetic changes are hypothesized to cause
altered disease risk via reprogramming the expression patterns
of key genes such as silencing tumor suppressors. Importantly,
these altered epigenetic marks can be metastable, and thus the
effects of altered gene expression and disease risk have the
potential to be transgenerational [20, 21]. Therefore, the asso-
ciation between prenatal iAs exposure and the development of
a wide variety of chronic diseases in adulthood is consistent
with iAs acting as a prenatal toxicant with widespread
epigenetic effects. Various arsenic species have been shown to
have effects on the epigenetic landscape outside the fetal envi-
ronment as well. As recently reviewed, some of these epigenetic
effects have been implicated as critical factors in the develop-
ment of diseases associated with chronic iAs exposure [22].
As the effects of arsenicals on the epigenome have been the
subjects of several reviews in recent years [22–24], the pur-
pose of the present review is to provide a critical evaluation of
the major trends in the more current literature (2011–2013) in
which the relationship between arsenic exposure and the
epigenome has been examined. Previous reviews have em-
phasized the following general findings associated with arsen-
ical exposure: (1) both global and gene-specific changes in
DNA methylation levels have been observed, (2) histones are
targeted for post-translational modifications, and (3) miRNA
levels are perturbed [22–24]. In the present review, we expand
upon this information and synthesize and evaluate the current
state of knowledge of arsenic-associated epigenetic modifica-
tions, particularly in the context of their biological signifi-
cance in disease development. While epigenetic perturbations
associated with iAs exposure were first reported in the 1980s
[25, 26], two papers published by the Mass and Waalkes
laboratories in 1997 marked the beginning of intensive inves-
tigations into the effects of arsenicals on the epigenome [27,
28]. As discussed in more detail below, while knowledge of
arsenical-induced epigenetic effects has advanced greatly over
the past 16 years, we are very much at the beginning of
understanding the functional consequences of these modifica-
tions, including the potential for specific modifications to
influence disease susceptibility as well as the potential herita-
bility of these effects.
Arsenic and DNA methylation
In mammals, DNA is methylated almost exclusively at the
cytosine residue of CpG-dinucleotides in which a single meth-
yl group is enzymatically transferred from S-adenosyl methi-
onine (SAM) to generate 5’-CpG-3’ [29]. CpGs are not dis-
tributed evenly throughout the mammalian genome, but in-
stead are clustered into two major regions: (1) ~15 % of CpGs
are found in regions of euchromatin known as CpG islands
and CpG island shores, and (2) ~85 % of CpGs are found in
repetitive interspersed regions of DNA (such as transposable
elements) in heterochromatin [30–32]. The best-understood
functional consequence of CpG methylation is gene silencing
at the transcriptional level. In general, a negative relationship
between promoter CpG island/CpG island shore methylation
and gene expression is observed [33], and CpGs are heavily
methylated in transcriptionally-silenced regions of hetero-
chromatin [32]. However, it should be noted the relationship
between DNAmethylation and gene expression is likely quite
complex, as there are numerous instances in which this
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relationship has been positive or no relationship has been
observed [33, 34].
To date, DNA methylation is the most extensively studied
epigenetic alteration in association with arsenic exposure,
which has included in vitro studies, in vivo studies, and
studies in human populations (as reviewed in [22–24]). Taken
together, studies have revealed that DNAmethylation patterns
can be altered by iAs and/or iAs metabolites at either the
global or gene-specific level. DNA methylation changes have
been detected in several genes implicated in iAs-associated
disease development, such as promoter hypermethylation of
tumor suppressors such as cyclin-dependent kinase inhibitor
2A (CDKN2A / p16 ) or tumor protein 53 (TP53 ) (as reviewed
in [22, 24]). In addition, global DNA hypomethylation, which
has been implicated as a contributing or predisposing factor of
carcinogenesis [35], has been observed upon exposure to
arsenic species, including cell lines malignantly transformed
by iAs in vitro [22, 36, 37]. However, in many cases, the
biological consequences of these changes (e.g., corresponding
changes in mRNA or protein levels) or significance of rela-
tionship (e.g., causal relationship between iAs exposure, DNA
methylation alterations, and malignant transformation) have
not been established. In addition, specific alterations are not
consistently observed across various experimental platforms
or studies, which may in part reflect the wide range of arsenic
doses and exposure times that have been utilized.
Aside from the examination of the promoter DNA methyla-
tion status of genes implicated in iAs-associated diseases, amajor
research focus has been the investigation of prenatal iAs expo-
sure on DNA methylation patterns. There is considerable exper-
imental evidence suggesting that iAs may act as a prenatal
toxicant by altering the DNA methylome. This is supported by
the observation that similar relationships between changes in
DNA methylation patterns and altered disease risk has been
observed with exposure to other prenatal toxicants or perturbed
prenatal nutritional status [38–42].
Another major area of interest has been the investigation of
the relationship between iAs biotransformation and the DNA
methylome. IAs biotransformation involves a series of alter-
nating reduction and oxidative methylation steps that yields
six major arsenicals found in the urine of humans and most
mammals, namely trivalent and pentavalent forms of iAs and
its monomethylated and dimethylated metabolites (MMAs
and DMAs, respectively) [43–45] (Fig. 1). These metabolites
vary in their toxicities, and as previously mentioned, the
efficiency of iAs biotransformation is believed to be an im-
portant factor in the development of iAs-associated diseases,
as several iAs metabolites are biologically reactive [6]. As the
same methyl donor source, namely SAM, is required for both
DNA methylation and iAs biotransformation, it has been
hypothesized that iAs biotransformation may influence dis-
ease risk by altering DNA methylation levels and therefore
influencing gene expression patterns [27, 28].
In recent years, examinations of the relationship be-
tween alterations in the DNA methylome and prenatal iAs
exposure and/or iAs biotransformation have continued as ma-
jor research thrusts (Table 1). As in earlier studies, many of
these investigations have also examined the DNA methylation
profiles of genes implicated in the development of iAs-
associated diseases. As discussed below, most of these studies
have not focused on mechanisms by which iAs may impact the
landscape of DNA methylation, but instead have examined the
DNA methylation profiles within the white blood cells of iAs-
exposed populations, including cord blood of prenatally ex-
posed newborns and peripheral blood isolated from chronically
exposed adults.
Our laboratory was interested in identifying genome-wide
gene-specific DNAmethylation changes associated with chron-
ic iAs exposure in humans. An examination of DNA methyla-
tion patterns in peripheral blood leukocytes (PBLs) from an
exposed population in Zimapán, Mexico, identified a set of 183
genes with differentially methylated promoters in women with
iAs-associated skin lesions vs. women with unlesioned skin
[46•]. Most of these genes had promoters that were
hypermethylated in women with skin lesions (99 %), and
several genes had been associated with iAs-induced diseases
such as diabetes mellitus, cardiovascular disease, and cancer.
The cancer-associated genes included a “tumor suppressorome”
complex containing 17 genes known to be silenced in various
human cancers. When these same blood samples were further
analyzed in relationship to urinary measurements of iAs,
MMAs, and DMAs, distinct patterns of DNA methylation
associated with levels of each of these arsenicals were observed
[47]. Interestingly, measurements of the percentage of glyco-
sylated hemoglobin in the blood (%HbA1c) of these women
indicated that 94 % were either pre-diabetic or diabetic, and we
observed an enrichment of genes with associations with type 1
and type 2 diabetes mellitus associated with one or more of
these urinary metabolites. These findings support the role of
the different iAs metabolites as factors influencing the
epigenome and highlight the need to investigate interindi-
vidual differences in iAs metabolism on epigenetic effects.
An interesting observation is that many of the identified
genes with iAs-associated DNA methylation changes have
similar functionality in the cell, and thus likely possess
common response elements for transcription factor binding.
To explain this phenomenon, the laboratory’s current hy-
pothesis is that toxicant-induced transcription factor occu-
pancy influences access of DNA methyltransferases to par-
ticular regions of the genome, resulting in “DNA methyla-
tion footprints” [48].
Other studies in exposed populations have linked iAs me-
tabolism to differences in DNA methylation patterns, includ-
ing two studies that have examined the relationship between
the DNA methylation patterns and polymorphisms in the
arsenic (+3 oxidation state) methyltransferase (AS3MT ) gene,
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which is the gene encoding the enzyme required for iAs
biotransformation (Fig. 1). In chronically-exposed women
living in the Argentinian Andes, a major AS3MT haplotype
associated with more efficient iAs metabolism was associated
with increased methylation of AS3MT and differential meth-
ylation of several other genes located on chromosome band
10q24 along with AS3MT [49]. Similar but weaker trends
were also identified in the cord blood of Bangladeshi new-
borns exposed to arsenic in utero [49].
A separate study examined the relationship between the
AS3MT haplotype, concentrations of urinary arsenicals, and
DNA methylation levels of the tumor suppressor gene p16 ,
the DNA repair gene mutL homolog 1, colon cancer,
nonpolyposis type 2 (E. coli ) (MLH1 ), and the Long Inter-
spersed Nuclear Element 1 (LINE-1) in the blood of chroni-
cally exposed women from the Argentinian Andes [50•]. A
significant positive relationship was observed between the
slow-metabolizing AS3MT haplotype and p16 methylation.
The concentration of total urinary arsenic (U-tAs; sum of iAs,
MMAs, DMAs) was associated with p16 andMLH1 methyl-
ation, urinary %iAs was positively associated with p16 meth-
ylation, and urinary %DMAs was negatively associated with
p16 methylation. Interestingly, although increased urinary
ratios of MMAs and/or high ratios of MMAs/DMAs are
associated with increased risk for a variety of iAs-associated
diseases [6], this study suggests iAs may have more toxic
effects than its metabolites on the methylation status of the
p16 promoter, at least in DNA isolated from blood. No
significant relationship was observed between LINE-1, used
as an indicator of global DNA methylation status, and urinary
arsenical measurements [50•].
One study investigated the promoter DNA methylation
level of the AS3MT promoter in Native Americans with low
vs. moderate U-tAs [51]. Out of 48 CpGs assayed in the
AS3MT promoter, a region was identified that contained 30
hypomethylated CpGs in the moderate U-tAs group compared
to the low U-tAs group, but there were no associations ob-
served between AS3MT promoter methylation levels and
%MMAs or %DMAs in urine. This study also revealed that
short-term exposure of peripheral blood mononuclear cells
(PBMCs) to sodium arsenite in vitro induced AS3MT expres-
sion, which was accompanied by a decrease in DNA methyl-
ation of the AS3MT promoter. In addition, AS3MT knock-
down inhibited arsenite-induced global DNA hypomethyla-
tion in PBMCs in vitro. While this study established a rela-
tionship between AS3MT promoter methylation status and
arsenic exposure in humans, further studies will be necessary
to determine if these DNA methylation alterations are associ-
ated with changes in AS3MT expression in human populations
and how these changes impact iAs biotransformation and risk
of iAs-associated disease development.
Several studies have examined the DNAmethylation status
of targeted genes including tumor suppressors and/or global
methylation of LINE-1 in the cord blood of exposed new-
borns. Analyses of cord blood from a cohort of newborns in
Thailand exposed to varying levels of iAs in utero identified a
positive relationship between arsenic exposure and TP53
promoter methylation status but not LINE-1 methylation sta-
tus [52]. The relationship between DNA methylation patterns
of LINE-1 and TP53 and p16 promoters were examined in
maternal and umbilical cord leukocytes isolated from iAs-
exposed mother-child pairs in Bangladesh [53]. Similar trends
were observed between DNA methylation trends collected
from maternal and newborn blood, in which there was a
positive association between maternal U-tAs levels and
LINE-1 methylation and some CpG sites within the p16
promoter. The data revealed evidence for a nonlinear dose-
response relationship, as these effects were most evident in the
middle tertiles of exposure. These data suggest that moderate
levels of iAs, which are likely relevant to many areas endemic
for arsenic poisoning, may have significant effects on DNA
methylation patterning that could result in genomic
alterations.
Supporting the impact of moderate levels of iAs exposure
on the epigenome are changes in DNA methylation observed
in a population exposed to relatively low levels of iAs. A
genome-wide examination of cord blood isolated from new-
borns from New Hampshire revealed that while no global
Fig. 1 Arsenic biotransformation in humans. Worldwide, the most prev-
alent source of arsenic exposure in humans is drinking water contaminat-
ed with inorganic arsenic (iAs), which exists in two oxidation states,
namely pentavalent arsenate (iAsV) and trivalent arsenite (iAsIII). IAsV is
reduced to iAsIII mainly in the blood or liver by one of several mammalian
enzymes that utilize glutathione (GSSH) or dithiothreitol (DTT) as re-
ductants. The remaining steps of iAs biotransformation, which involve
alternating oxidative methylation and reduction steps, occur mainly in the
liver. In this process, iAsIII undergoes an oxidative methylation step
catalyzed by arsenic (+3 oxidation state) methyltransferase (AS3MT) to
produce monomethylarsonic acid (MMAV). MMAV is subsequently re-
duced to monomethylarsonous acid (MMAIII), which is the substrate for
another round of oxidative methylation and reduction in which
dimethylarsinic acid (DMAV) and dimethylarsinous acid (DMAIII), re-
spectively, are produced. AS3MT has been shown to catalyze both the
oxidative methylation and successive reduction reactions using s-
adenosyl methionine (SAM) as a methyl donor and various molecules
such as nicotinamide adenine dinucleotide phosphate (NADPH),
thioredoxin, DTT, or GSH as reductants (2e-) [43, 45]. In general, total
urinary arsenic in iAs-exposed individuals is composed of 10–20 % total
(i.e. trivalent + pentavalent) iAs, 10–20 % total MMAs, and 60–80 %
total DMAs [44]. (Modified from: Bailey KA and Fry RC, Arsenic-
induced Changes to the Epigenome, in Toxicology and Epigenetics,
S.C. Sahu, Editor. 2012, John Wiley & Sons, Ltd.: Chichester, UK) [22]
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effects on DNA methylation were observed in relationship to
maternal U-tAs levels, most of the U-tAs-associated effects
were observed in CpG islands [54•]. Of the CpG islands
tested, 18 % were differentially methylated among newborns
associated with different maternal U-tAs levels, and the DNA
methylation status of several of these CpG islands had linear
relationships with maternal U-tAs [54•]. Interestingly, a po-
tential sex-dependent relationship was observed between ma-
ternal U-tAs levels and global cord blood DNAmethylation in
Bangladeshi newborns [55•]. While there was a positive rela-
tionship between maternal U-tAs levels and global cord blood
DNA methylation in all newborns in the study, when the
newborns were divided by sex, this relationship was positive
for males and negative for females. If the identified changes in
DNA methylation levels are, indeed, functional and impact
gene/protein expression, these alterations may influence dif-
ferential susceptibility to iAs-induced disease in males and
females, a feature observed in various cohorts exposed to iAs.
Taken together, these studies are informative, as they reveal
that even low to moderate levels of iAs exposure can impact
the DNA methylation landscape. They also highlight the
intriguing finding that some of these effects may be sex-
dependent and suggest an association between iAs metabo-
lism and DNA methylation patterns.
There are a few caveats to consider when interpreting the
existing body of literature related to arsenical-associated
changes in DNA methylation patterning. For example, al-
though PBL DNA methylation profiles may serve as useful
biomarkers for iAs exposure, disease state, and/or disease
susceptibility, it is currently unknown whether PBL DNA
methylation profiles reflect those that would be present in
target cells of iAs toxicity such as liver, lung, and bladder. In
addition, it is important to note that multiple white blood cell
types are present in PBL preparations, and these cell popula-
tions may shift upon exposure to iAs or due to other environ-
mental factors. It is also unknown if the gene-specific DNA
methylation changes correspond to changes in mRNA or
protein levels of their genes. Additionally, the relationship
between DNA methylation and gene expression is more com-
plex than often considered, where increased DNAmethylation
may be associated with increased gene expression. There is
currently limited information on the stability of the DNA
methylation changes over time. Also, in the case of prenatal
iAs exposure, the studies presented thus far do not investigate
true transgenerational effects, as iAs can readily pass through
the placenta [56, 57], and thus warrant an assessment of
transgenerational effects of various iAs-associated phenotypes
that persist to the F3 generation and beyond. It is important to
note, therefore, that while the available studies serve as a
critical foundation for understanding the association between
iAs exposure and the epigenome, future studies will be nec-
essary to examine the relationship between these alterations
and the development of iAs-associated disease.
Arsenic and histone post-translational modifications
(PTMs)
Histones play an essential role in the compaction and organi-
zation of the genome and in the regulation of gene activity.
Histones comprise the protein component of the nucleosome,
which is the fundamental repeating unit of chromatin. The
nucleosome contains ~146 bp of DNA wrapped around a
histone octamer comprising two copies each of the four core
histones H2A, H2B, H3, and H4 [58]. Each of the four core
histones contains unstructured amino-terminal (N-terminal)
and carboxy-terminal (C-terminal) tails, and specific amino
acids within those tails are targets of post-translational modi-
fications (PTMs) [59]. Each histone may havemultiple PTMs,
which collectively comprise the “histone code” of a region
and therefore influence its transcriptional competency via
effects on nucleosome structure/positioning and by acting as
protein-binding targets [60]. While multiple PTMs have been
identified, those that are the most extensively studied and best
understood in the context of transcriptional competency are
histone phosphorylation, methylation, acetylation, and
ubiquitination [61].
Most of the investigations into the effects of arsenicals on
histone PTMs have been performed in vitro , in which changes
in both global and gene-specific histone PTM patterns have
been observed (as reviewed in [22]). Of note, several of these
gene-specific histone PTM alterations have identified a rela-
tionship between arsenic exposure, the acquisition of targeted
promoter histone PTM marks and DNA methylation patterns,
and transcriptional competency. In at least one example, al-
tered histone PTMs and the altered expression of a particular
gene were associated with the toxic effects of arsenic. For
instance, the arsenical-mediated malignant transformation of a
human urothelial cell line was associated with aberrant pro-
moter histone PTMs and overexpression of a key gene, name-
ly wingless-type MMTV integration site family, member 5A
(WNT5A), which is essential for the maintenance of the ma-
lignant phenotype [62].
As observed in the case of DNA methylation, recent years
have witnessed an increase in the number of studies that have
examined histone PTMs in iAs-exposed populations (Table 2).
For instance, a positive association was observed among steel
workers exposed to inhalable metal-rich particles between
arsenic and nickel exposure and global PBL histone H3 lysine
4 dimethylation (H3K4me2) and histone 3 lysine 9 acetylation
(H3K9ac) in PBLs [63]. A study of iAs-exposed individuals
in Bangladesh revealed that some arsenic-associated changes
in histone PTMswere common across all individuals, whereas
others were sex-specific [64•]. For instance, U-tAs levels were
positively associated with the transcription-restrictive PTM
histone 3 lysine 9 dimethylation (H3K9me2) and negatively
associated with the transcription-permissive histone PTM his-
tone 3 lysine 9 acetylation (H3K9ac) in the PBLs of both men
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and women. The authors point out that the positive association
of H3K9me2 with U-tAs is particularly interesting in light of
the DNA hypermethylation of LINE-1 elements in iAs-
exposed mother-child pairs in Bangladesh [53], as
H3K9me2 is a marker for DNA methylation. Therefore, data
from these two studies are consistent with arsenic-associated
epigenetic effects that may favor overall transcriptional repres-
sion [64•]. However, in addition to trends observed for spe-
cific histone PTMs in bothmen and women, four other histone
PTMs were identified that exhibited sex-dependent associa-
tions with levels of iAs in drinking water [64•].
One study in mice indicated that changes in promoter
PTMs are not always associated with changes in DNA meth-
ylation patterns. Long-term (6 months) exposure to iAs result-
ed in the downregulation of p16 mRNA in the livers of
C57BL/6 mice, which was accompanied by an increase of
the transcription-restrictive PTM H3K9me2 in the p16 pro-
moter region but no change in promoter DNA methylation
status [65•].
Together, these recent studies demonstrated that exposure
to iAs is associated with genome-wide changes in histone
PTMs in animals and humans and that some of these effects
in humans may be sex-specific. Importantly, mechanistic
in vitro and in vivo studies have provided important ground-
work for studying the relationship between iAs exposure,
changes in histone PTMs, and potentially toxic effects, such
as the transcriptional modulation of genes implicated in dis-
ease development (e.g., tumor suppressor p16 ). The relation-
ship between these events and iAs-associated disease devel-
opment must be addressed in future work. In addition, the
studies highlighted here underscore the need to examine the
interplay between multiple epigenetic components that likely
work in unison to mediate the toxic effects of arsenicals.
Arsenic and microRNAs (miRNAs)
miRNAs are non-coding RNAs 21–24 nucleotides in length
that are best characterized as regulators of gene activity at the
post-transcriptional level, although they have been shown to
regulate gene expression at the transcriptional level as well
[66, 67]. At the post-transcriptional level, miRNAs bind to the
3’ untranslated region (3’ UTR) of mRNAs, which can alter
mRNA function by interfering with mRNA translation into
protein or by targeting mRNAs for degradation [68]. The
regulation ofmiRNA expression is complex, asmiRNA levels
are controlled not only at the transcriptional level but also
post-transcriptionally, where they undergo multiple process-
ing steps to yield mature miRNAs [69]. Approximately 2000
mature miRNAs have been identified in humans [70], and by
analyzing conserved miRNA binding sites within the 3’UTR,
it is believed that >60 % of protein-encoding human genes are
targets of miRNAs [71].
The effects of iAs on miRNA levels have been relatively
unexplored in comparison to other epigenetic modifications,
particularly as they relate to chronic disease development in
humans (as reviewed in [22]). Previous reviews have
highlighted that most studies of the effects of arsenical expo-
sure on miRNAs have been performed in vitro , and few have
investigated the functional consequences of these perturba-
tions [22, 23]. In recent years, in vitro studies have continued
to predominate, but many are mechanistic in nature, in which
miRNAs have been implicated in mediating various toxic
effects of arsenicals (Table 3).
Some of these studies have focused on miRNAs as medi-
ators of the apoptotic effects of arsenic trioxide (ATO) [72,
73], a chemotherapeutic agent used in the treatment of re-
lapsed or refractory acute promyelocytic leukemia [74]. Other
studies have indicated miRNAs may play roles in the diverse
toxic effects of iAs. For instance, miR-9 and miR-181b were
implicated as promoting abnormal angiogenesis in iAs-
exposed chick embryos [75], and specific miRNAs have been
implicated in iAs-mediated carcinogenesis. As an example,
the reduction of miR-200b was shown to be essential for the
iAs-mediated malignant transformation of TP53-deficient hu-
man bronchial epithelial cells [76]. Interestingly, the iAs-
mediated miR-200b reduction was accompanied by increased
methylation of the miR-200 promoter [76], highlighting the
potential interplay between multiple forms of epigenetic reg-
ulation on gene expression. IAs was also found to inducemiR-
190 in a dose-dependent manner in a human bronchial cell
line, in which miR-190 overexpression was shown to enhance
malignant characteristics [77]. This study also identified a
target of miR-190, namely mRNA of the PH domain
leucine-rich repeat protein phosphatase (PHLPP) gene, which
has known tumor suppressor functions. Another study identi-
fied the upregulation of miR-21 as an important event in the
iAs-mediated transformation of human embryo lung fibro-
blast cells, which was dependent on the activation of ROS-
sensitive pathways involving extracellular signal-regulated
kinase mitogen-activated protein kinase (ERK/MAPK) and
transcription factor nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) [78•].
Together, these studies indicate that miRNAs may be in-
volved in mediating multiple toxic effects of arsenic species,
including the modulation of pathways that control cell growth,
differentiation, and apoptosis. The studies also provide insight
regarding the involvement of epigenetic modifications and
cellular signaling pathways in the modulation of miRNA
levels in response to iAs exposure. Future research could
elucidate the mechanisms by which iAs can perturb miRNA
expression levels and assess whether such expression is al-
tered in biological samples from humans. As with the other
forms of epigenetic modifications, it will be critical to confirm
the functional consequences of changes in the expression of
miRNAs on the expression of their transcriptional targets and
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to determine whether these changes ultimately influence pro-
tein abundance and function.
Conclusions and future directions
In summary, current literature clearly indicates that arsenic
exposure is associated with changes that include altered pat-
terns of DNA methylation (both global and gene-specific),
modifications of histone PTMs, and altered expression levels
of miRNAs. Importantly, answers to some key questions
remain unknown: (1)What is the relationship of the epigenetic
changes to disease ?-The significance of these arsenic-
associated epigenetic effects on human disease development
is likely dependent on a number of factors, including geno-
type, combined exposures to other contaminants, and other
environmental influences such as nutrition; (2) How do the
epigenetic changes influence disease directly?-While many
associations have been established, it is largely unknown if
there is a causal relationship between the epigenetic changes
and arsenic-associated disease development, as well as the
mechanisms by which these changes cause disease; (3) How
stable are the epigenetic changes and are they functional?-It
is important to consider that some epigenetic changes may be
adaptive or stochastic responses that do not promote disease
development. Likewise, global and/or gene-specific changes
in DNAmethylation patterning and histone PTMs may not be
reflective of functional changes that are manifested at the
protein level. Of note, it is important to consider that several
major research trends have emerged in recent years. For
instance, the DNAmethylation studies were almost exclusive-
ly conducted on samples from human populations, whereas
the miRNA studies were dominated by in vitro studies. These
trends reveal gaps in research that must be closed in order to
fully understand the molecular mechanisms that drive
arsenical-associated epigenetic alterations, the consistency of
these alterations across experimental platforms and study type
(e.g., in vitro studies, in vivo studies, human studies), and
ultimately, the relevance of these alterations to altered disease
risk in exposed populations. Lastly, it will be increasingly
important to examine the effects of arsenicals at a systems-
wide level, where the impacts of both epigenetic and non-
epigenetic alterations are examined. It is likely that the true
biological picture of the epigenetic contributions to the mech-
anism of iAs-induced disease represents the complex interplay
of a multitude of signaling events within the cell.
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